ClinicalTrials.Veeva

Menu

FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff

U

University of Alberta

Status and phase

Completed
Phase 3
Phase 2

Conditions

Enterocolitis Clostridium Difficile Recurrent

Treatments

Biological: Fecal Microbiota Transplant

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Delivery of FMT by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully. Endoscopic delivery requires significant health care utilization and associated cost. Therefore, it is extremely desirable if FMT can be infused by a non invasive modality, which would significantly reduce patient discomfort, procedure related risks and health care costs, while offering similar efficacy to colonoscopic delivery in the range of 90%.

Full description

Patients with minimum 3 episodes of Clostridium difficile within 6 months are randomized 1:1 to received FMT by either colonoscopy or capsules. Pts are assessed at 1 week, 2 weeks, 1 mon, 3 mon, 6 mon and 1 year post FMT. Stool, urine and blood samples are collected. Medical cost for previous treatment is collected as well at pt perspective and QoL.

Enrollment

116 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age > 18 and < 90 years at the time of Screening.
  2. Diagnosis of at least 3 episodes of recurrent CDI, with each episode defined as presence of diarrhea (> 3 unformed stools/24 hours) associate with positive stool Clostridium difficle toxin, occurring within 3 months of each other.
  3. CDI infection under symptomatic control with < 3 loose/unformed BM's per 24 h period for at least 2 consecutive days before procedure.
  4. Those with ability to provide informed consent.

Exclusion criteria

  1. Those with complicated CDI, defined as white blood cell>35 or <0.5 x 109/L, significant abdominal pain and distension with evidence of toxic megacolon or pseudomembranous colitis, hypotension defined as systolic blood pressure < 90 mmHg unresponsive to fluid resuscitation, end organ failure, or requiring intensive care unit admission.
  2. Those with chronic diarrheal illness, such as irritable bowel syndrome or inflammatory bowel disease unless they are in remission for at least 3 months prior to enrollment.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

116 participants in 2 patient groups

Delivery via capsule
Experimental group
Description:
Fecal microbiota transplant is delivered by oral capsules
Treatment:
Biological: Fecal Microbiota Transplant
Delivery via colonoscopy
Experimental group
Description:
Fecal microbiota transplant delivered by colonoscopy
Treatment:
Biological: Fecal Microbiota Transplant

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems